Search results
Results from the WOW.Com Content Network
An article published by the journal Nature on 6 July 2021 cited data released by the United Arab Emirates on some 81,000 individuals who had received Sputnik V, according to which the vaccine demonstrated an efficacy of 97.8% in preventing symptomatic COVID-19, and 100% efficacy in preventing severe complications.
The head of the Russian Direct Investment Fund (RDIF) stated that 20 countries had requested in total 1 billion doses of the vaccine, nicknamed Sputnik V. [11] On August 20 registration was called "conditional" with final registration depends on results of Phase 3 trial, [12] such registration is limited and allowed by Decree 441 for medicines ...
On 29 June 2021, the director of the Gamaleya Institute, Denis Logunov, said that Sputnik V is about 90% effective against the Delta variant. [81] On July 21, researchers from PHE published a study finding that the Pfizer vaccine was 93.7% effective against symptomatic disease from Delta after 2 doses, while the Astrazeneca vaccine was 67% ...
Russia was quick to develop its two-dose Sputnik V vaccine last year and has also deployed a one-shot Sputnik Light vaccine, both of which have it says demonstrated high efficacy in trials, but ...
Vaccines from AstraZeneca , Russia's Gamaleya Institute and Johnson & Johnson fight the coronavirus with another virus, leaving scientists concerned the shots may lose potency if annual ...
Alexander Gintsburg is the head of the Gamaleya Institute -- the organization that produced Russia's Sputnik V vaccine. Its development is coming at a rapid pace -- amid what he calls "wartime ...
A vaccine is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval. [6] As of September 2021, no study on Sputnik Light reported confidence intervals, so it is not possible to know the accuracy of the estimates. Effectiveness is generally expected to slowly decrease over time. [7]
Retrospective cohort study of the effectiveness of two Russian vaccines against the SARS-CoV-2 Delta variant in Moscow (June–July 2021) proved that EpiVacCorona, unlike Sputnik V, is an ineffective vaccine and therefore cannot protect against COVID-19. [4]